ASX - By Stock
|
PER |
Re:
Ann: Percheron appoints Dr Cathryn Clary as Chief Medical Advisor
|
|
Drian
|
43 |
10K |
0 |
03/06/24 |
03/06/24 |
ASX - By Stock
|
43
|
10K
|
0
|
|
ASX - By Stock
|
TLX |
Re:
Ann: Telix Completes TLX250-CDx (Zircaix) BLA Submission
|
|
Drian
|
32 |
8.4K |
2 |
03/06/24 |
03/06/24 |
ASX - By Stock
|
32
|
8.4K
|
2
|
|
ASX - By Stock
|
PER |
Re:
Ann: Percheron appoints Dr Cathryn Clary as Chief Medical Advisor
|
|
Drian
|
43 |
10K |
1 |
03/06/24 |
03/06/24 |
ASX - By Stock
|
43
|
10K
|
1
|
|
ASX - By Stock
|
TLX |
Re:
Ann: ProstACT SELECT Study of TLX591 rADC Therapy - Positive rPFS
|
|
Drian
|
148 |
44K |
1 |
03/06/24 |
03/06/24 |
ASX - By Stock
|
148
|
44K
|
1
|
|
ASX - By Stock
|
TLX |
Re:
Ann: ProstACT SELECT Study of TLX591 rADC Therapy - Positive rPFS
|
|
Drian
|
148 |
44K |
0 |
03/06/24 |
03/06/24 |
ASX - By Stock
|
148
|
44K
|
0
|
|
ASX - By Stock
|
TLX |
Re:
Ann: ProstACT SELECT Study of TLX591 rADC Therapy - Positive rPFS
|
|
Drian
|
148 |
44K |
0 |
03/06/24 |
03/06/24 |
ASX - By Stock
|
148
|
44K
|
0
|
|
ASX - By Stock
|
TLX |
Re:
Ann: ProstACT SELECT Study of TLX591 rADC Therapy - Positive rPFS
|
|
Drian
|
148 |
44K |
0 |
03/06/24 |
03/06/24 |
ASX - By Stock
|
148
|
44K
|
0
|
|
ASX - By Stock
|
TLX |
Re:
Ann: ProstACT SELECT Study of TLX591 rADC Therapy - Positive rPFS
|
|
Drian
|
148 |
44K |
0 |
31/05/24 |
31/05/24 |
ASX - By Stock
|
148
|
44K
|
0
|
|
ASX - By Stock
|
TLX |
Re:
Ann: ProstACT SELECT Study of TLX591 rADC Therapy - Positive rPFS
|
|
Drian
|
148 |
44K |
7 |
31/05/24 |
31/05/24 |
ASX - By Stock
|
148
|
44K
|
7
|
|
ASX - By Stock
|
CU6 |
Re:
Ann: Clarity strengthens Cu-64 network with new supply agreement
|
|
Drian
|
50 |
13K |
4 |
30/05/24 |
30/05/24 |
ASX - By Stock
|
50
|
13K
|
4
|
|
ASX - By Stock
|
CU6 |
Re:
Research/Valuation
|
|
Drian
|
473 |
153K |
6 |
28/05/24 |
28/05/24 |
ASX - By Stock
|
473
|
153K
|
6
|
|
ASX - By Stock
|
PTX |
Re:
Ann: PTX invited to present at international lymphoma forum
|
|
Drian
|
23 |
9.3K |
0 |
22/05/24 |
22/05/24 |
ASX - By Stock
|
23
|
9.3K
|
0
|
|
ASX - By Stock
|
TLX Biotech |
Re:
Understanding Telix
|
|
Drian
|
937 |
427K |
0 |
22/05/24 |
22/05/24 |
ASX - By Stock
|
937
|
427K
|
0
|
|
ASX - By Stock
|
TLX Biotech |
Re:
Understanding Telix
|
|
Drian
|
937 |
427K |
5 |
15/05/24 |
15/05/24 |
ASX - By Stock
|
937
|
427K
|
5
|
|
ASX - By Stock
|
TLX |
Re:
Ann: Telix Q1 2024 Revenue and Business Update
|
|
Drian
|
153 |
60K |
3 |
13/05/24 |
13/05/24 |
ASX - By Stock
|
153
|
60K
|
3
|
|
ASX - By Stock
|
TLX Biotech |
Re:
Understanding Telix
|
|
Drian
|
937 |
427K |
13 |
06/05/24 |
06/05/24 |
ASX - By Stock
|
937
|
427K
|
13
|
|
ASX - By Stock
|
TLX Biotech |
Re:
Understanding Telix
|
|
Drian
|
937 |
427K |
8 |
06/05/24 |
06/05/24 |
ASX - By Stock
|
937
|
427K
|
8
|
|
ASX - By Stock
|
TLX Biotech |
Re:
Understanding Telix
|
|
Drian
|
937 |
427K |
13 |
22/04/24 |
22/04/24 |
ASX - By Stock
|
937
|
427K
|
13
|
|
ASX - By Stock
|
TLX |
Re:
Ann: Telix Q1 2024 Revenue and Business Update
|
|
Drian
|
153 |
60K |
3 |
18/04/24 |
18/04/24 |
ASX - By Stock
|
153
|
60K
|
3
|
|
ASX - By Stock
|
CU6 |
Tlx buys ARTMS - effect on CU-64?
|
|
Drian
|
47 |
14K |
6 |
05/03/24 |
05/03/24 |
ASX - By Stock
|
47
|
14K
|
6
|
|
ASX - By Stock
|
TLX |
Re:
Ann: Telix to Acquire ARTMS (Isotope Production Platform)
|
|
Drian
|
43 |
17K |
1 |
05/03/24 |
05/03/24 |
ASX - By Stock
|
43
|
17K
|
1
|
|
ASX - By Stock
|
TLX Biotech |
Re:
Understanding Telix
|
|
Drian
|
937 |
427K |
3 |
04/03/24 |
04/03/24 |
ASX - By Stock
|
937
|
427K
|
3
|
|
ASX - By Stock
|
TLX |
Re:
Ann: Telix 2023 Full Year Results and Investor Webcast/Call
|
|
Drian
|
130 |
43K |
1 |
22/02/24 |
22/02/24 |
ASX - By Stock
|
130
|
43K
|
1
|
|
ASX - By Stock
|
TLX |
Re:
Ann: Telix 2023 Full Year Results and Investor Webcast/Call
|
|
Drian
|
130 |
43K |
0 |
22/02/24 |
22/02/24 |
ASX - By Stock
|
130
|
43K
|
0
|
|
ASX - By Stock
|
TLX |
Re:
Ann: Telix 2023 Full Year Results and Investor Webcast/Call
|
|
Drian
|
130 |
43K |
0 |
22/02/24 |
22/02/24 |
ASX - By Stock
|
130
|
43K
|
0
|
|
ASX - By Stock
|
TLX |
Re:
Ann: Presentation to Accompany QSAM Acquisition
|
|
Drian
|
23 |
12K |
4 |
15/02/24 |
15/02/24 |
ASX - By Stock
|
23
|
12K
|
4
|
|
ASX - By Stock
|
TLX |
Re:
Ann: Telix Submits BLA for TLX250-CDx for Kidney Cancer Imaging
|
|
Drian
|
44 |
14K |
4 |
19/12/23 |
19/12/23 |
ASX - By Stock
|
44
|
14K
|
4
|
|
ASX - By Stock
|
TLX |
Re:
Ann: Telix Submits BLA for TLX250-CDx for Kidney Cancer Imaging
|
|
Drian
|
44 |
14K |
0 |
19/12/23 |
19/12/23 |
ASX - By Stock
|
44
|
14K
|
0
|
|
ASX - By Stock
|
TLX |
Re:
TLX Chart
|
|
Drian
|
1.5K |
583K |
1 |
12/12/23 |
12/12/23 |
ASX - By Stock
|
1.5K
|
583K
|
1
|
|
ASX - By Stock
|
TLX |
Re:
TLX Chart
|
|
Drian
|
1.5K |
583K |
0 |
12/12/23 |
12/12/23 |
ASX - By Stock
|
1.5K
|
583K
|
0
|
|
ASX - By Stock
|
CU6 |
Re:
Ann: undetectable PSA level with Cu-67 SAR-bisPSMA
|
|
Drian
|
62 |
18K |
6 |
01/12/23 |
01/12/23 |
ASX - By Stock
|
62
|
18K
|
6
|
|
ASX - By Stock
|
TLX |
Re:
Ann: Presentation to Accompany AI Development Program Update
|
|
Drian
|
68 |
31K |
5 |
10/11/23 |
10/11/23 |
ASX - By Stock
|
68
|
31K
|
5
|
|
ASX - By Stock
|
TLX |
Re:
Ann: Presentation to Accompany AI Development Program Update
|
|
Drian
|
68 |
31K |
0 |
09/11/23 |
09/11/23 |
ASX - By Stock
|
68
|
31K
|
0
|
|
ASX - By Stock
|
TLX |
Re:
Ann: Presentation to Accompany AI Development Program Update
|
|
Drian
|
68 |
31K |
0 |
09/11/23 |
09/11/23 |
ASX - By Stock
|
68
|
31K
|
0
|
|
ASX - By Stock
|
TLX |
Re:
Ann: Presentation to Accompany AI Development Program Update
|
|
Drian
|
68 |
31K |
0 |
09/11/23 |
09/11/23 |
ASX - By Stock
|
68
|
31K
|
0
|
|
ASX - By Stock
|
TLX |
Re:
TLX Chart
|
|
Drian
|
1.5K |
583K |
14 |
23/10/23 |
23/10/23 |
ASX - By Stock
|
1.5K
|
583K
|
14
|
|
ASX - By Stock
|
TLX |
Re:
Eli Lily to acquire radio-harms company Point Biopharma for $US1.4 billion
|
|
Drian
|
10 |
4.5K |
4 |
05/10/23 |
05/10/23 |
ASX - By Stock
|
10
|
4.5K
|
4
|
|
ASX - By Stock
|
TLX |
Re:
Competition
|
|
Drian
|
254 |
115K |
3 |
22/09/23 |
22/09/23 |
ASX - By Stock
|
254
|
115K
|
3
|
|
ASX - By Stock
|
TLX |
Re:
Competition
|
|
Drian
|
254 |
115K |
0 |
22/09/23 |
22/09/23 |
ASX - By Stock
|
254
|
115K
|
0
|
|
ASX - By Stock
|
TLX |
Re:
Competition
|
|
Drian
|
254 |
115K |
0 |
22/09/23 |
22/09/23 |
ASX - By Stock
|
254
|
115K
|
0
|
|
ASX - By Stock
|
CU6 |
Re:
CU6 - General discussion
|
|
Drian
|
362 |
127K |
1 |
20/09/23 |
20/09/23 |
ASX - By Stock
|
362
|
127K
|
1
|
|
ASX - By Stock
|
OSL |
Re:
Ann: Appendix 4E and Annual Report
|
|
Drian
|
31 |
12K |
2 |
07/09/23 |
07/09/23 |
ASX - By Stock
|
31
|
12K
|
2
|
|
ASX - By Stock
|
OSL |
Re:
Ann: Appendix 4E and Annual Report
|
|
Drian
|
31 |
12K |
3 |
07/09/23 |
07/09/23 |
ASX - By Stock
|
31
|
12K
|
3
|
|
ASX - By Stock
|
OSL |
Re:
Ann: Appendix 4E and Annual Report
|
|
Drian
|
31 |
12K |
0 |
07/09/23 |
07/09/23 |
ASX - By Stock
|
31
|
12K
|
0
|
|
ASX - By Stock
|
TLX Biotech |
Re:
Understanding Telix
|
|
Drian
|
937 |
427K |
10 |
02/09/23 |
02/09/23 |
ASX - By Stock
|
937
|
427K
|
10
|
|
ASX - By Stock
|
CU6 |
Re:
ASX: CU6 Outlook.
|
|
Drian
|
73 |
35K |
2 |
25/08/23 |
25/08/23 |
ASX - By Stock
|
73
|
35K
|
2
|
|
ASX - By Stock
|
CU6 |
Re:
ASX: CU6 Outlook.
|
|
Drian
|
73 |
35K |
12 |
25/08/23 |
25/08/23 |
ASX - By Stock
|
73
|
35K
|
12
|
|
ASX - By Stock
|
TLX |
Re:
Ann: 1H 2023 Results Presentation
|
|
Drian
|
102 |
30K |
4 |
24/08/23 |
24/08/23 |
ASX - By Stock
|
102
|
30K
|
4
|
|
ASX - By Stock
|
TLX |
Re:
Ann: 1H 2023 Results Presentation
|
|
Drian
|
102 |
30K |
10 |
24/08/23 |
24/08/23 |
ASX - By Stock
|
102
|
30K
|
10
|
|
ASX - By Stock
|
RAD |
Re:
Ann: EGM Presentation
|
|
Drian
|
13 |
4.8K |
1 |
18/08/23 |
18/08/23 |
ASX - By Stock
|
13
|
4.8K
|
1
|
|